PEG10

Across TCGA pan-cancer cohorts, PEG10 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PEG10 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PEG10 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PEG10 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

PDAC, LUAD, and GBM are the cancer types where PEG10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.344	0.731	<.001	57	view →
LUAD	OS	Median	II,III,IV	0.803	0.491	.020	11	view →
GBM	OS	Median	All	0.657	0.384	.009	7	view →
UCEC	OS	Quartile	All	1.000	0.853	.044	2	view →
HNSC	OS	Tertile	IV	0.976	0.788	.040	2	view →
CCRCC	DFS	Quartile	II,III,IV	0.766	0.944	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PEG10–PDAC (OS)

Open the PDAC breakdown →